Clinical trial · Interventional
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies
NCT04164199CI-TRIAL-00113410completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (13)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BAT1706 | Drug | Bevacizumab | ALIAS |
| BGB-15025 | Drug | — | UNRESOLVED |
| BGB-A445 | Drug | — | UNRESOLVED |
| Fruquintinib | Drug | Fruquintinib | ALIAS |
| LBL-007 | Drug | — | UNRESOLVED |
| Lenvatinib | Drug | Lenvatinib | ALIAS |
| Ociperlimab | Drug | — | UNRESOLVED |
| Pamiparib | Drug | — | UNRESOLVED |
| Sitravatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (18)
- type
- EXPERIMENTAL
- label
- A - Tislelizumab Monotherapy
- interventionNames
- Drug: Tislelizumab
- type
- EXPERIMENTAL
- label
- B - Pamiparib Monotherapy
- interventionNames
- Drug: Pamiparib
- type
- EXPERIMENTAL
- label
- C - Sitravatinib Monotherapy
- interventionNames
- Drug: Sitravatinib
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: 1. Currently participating in a BeiGene- or BeOne-sponsored eligible parent study 2. Fulfills treatment criteria specified in the parent study protocol 3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments. 4. The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study: 1. "Treatment interruption" is an unplanned pause in study treatment (eg, due to adverse event). Restarting study treatment beyond the interruption period allowed by the parent study will be determined by the investigator and the sponsor. Key Exclusion Criteria: 1. Permanently discontinued from all investigational drugs in the parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent 2. Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy prior to the start of the extension study 3. Have a medical condition or organ system dysfunction that in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of investigational drugs, or put the study outcomes at undue risk 4. Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study 5. Pregnant or lactating women NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.